Medical Doctor Program year 2024 Reported 2019–2024 Source: CMS Open Payments, 2026 publication

Tingting Wong

Infectious Disease Brooklyn, NY Medical Doctor

NPI 1174862866 CMS profile 5695859

7400 18Th Ave, Brooklyn, NY 11204

Open in the dashboard

General payments

$1,137

48 records reported · program years 2019–2024

Research payments

$0

Paid to them · None reported · program years 2019–2024

Ownership & investment interest

$0

None reported

Through program year 2024, Tingting Wong of Brooklyn, NY is reported in the CMS Open Payments database as having received $1,137 across 48 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 64th percentile of Infectious Disease profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

4 rows
Year Kind Relative to this record's peak year Amount Records
2024 General $23 1
2021 General $511 22
2020 General $283 13
2019 General $320 12

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Tingting Wong
  • Infectious Disease median
  • Middle half of Infectious Disease
  • National median

In program year 2025, general payments to Tingting Wong were reported at $0. Among 3,905 Infectious Disease profiles paid that year, the median was $188 and the middle half received between $57 and $766.

Show as a table
Year Tingting Wong Infectious Disease median Middle half National median
2019 $320 $190 $60–$862 $163
2020 $283 $124 $32–$606 $114
2021 $511 $148 $38–$905 $132
2022 $0 $166 $50–$834 $149
2023 $0 $171 $57–$787 $160
2024 $23 $176 $52–$752 $164
2025 $0 $188 $57–$766 $169

Breakdown

Who paid General payments · program years 2019–2024
  1. Janssen Biotech, Inc. $1,042 46 payments
  2. Janssen Products, LP $72 1 payment
  3. Gilead Sciences, Inc. $23 1 payment

Every payment, record by record

What the payments were for General payments · program years 2019–2024
  1. Food and Beverage $1,137 48 payments
Products named General payments · program years 2019–2024
  1. SYMTUZA $1,114 47 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 76 drugs

Part D claims

2,498

Median for Infectious Disease: 268

Drug cost

$1,911,318

Median for Infectious Disease: $217,595

Branded share of claims

39.6%

Median for Infectious Disease: 45.5%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Biktarvy Bictegrav/Emtricit/Tenofov Ala Brand 88 $375,865
Odefsey Emtricitab/Rilpiviri/Tenof Ala Brand 84 $305,267
Juluca Dolutegravir/Rilpivirine Brand 74 $289,399
Genvoya Elviteg/Cob/Emtri/Tenof Alafen Brand 46 $181,609
Prezcobix Darunavir/Cobicistat Brand 72 $174,462
Tivicay Dolutegravir Sodium Brand 69 $152,189
Descovy Emtricitabine/Tenofov Alafenam Brand 47 $139,033
Cabenuva Cabotegravir/Rilpivirine Brand 13 $76,599
Triumeq Abacavir/Dolutegravir/Lamivudi Brand 16 $55,453
Prezista Darunavir Brand 16 $33,649

The 10 drugs with the highest cost, of 76 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 5,546 Part D prescribers listed as Infectious Disease; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 31 billing codes

Paid by Medicare

$216,178

Of which drugs: $1,997

Medicare patients

428

Average age 75

Services billed

2,562

234 women, 194 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Diabetes 66%
Arthritis 58%
Chronic kidney disease 54%
Ischemic heart disease 52%
Heart failure 46%
Depression 36%
Atrial fibrillation 32%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Vaccine for influenza for injection into muscle 90653 Office 13 13 $1,064

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

48 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Infectious Disease in New York

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2024

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record